Inclusion Criteria

DISEASE CHARACTERISTICS:

- Diagnosis of relapsed or refractory multiple myeloma

- Measurable or evaluable disease as defined by ≥ 1 of the following:

- Serum monoclonal protein ≥ 1.0 g by protein electrophoresis

- Monoclonal protein ≥ 200 mg by 24-hour urine electrophoresis

- Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum
immunoglobulin kappa to lambda free light chain ratio

- Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)

- No concurrent amyloidosis

PATIENT CHARACTERISTICS:

- ECOG performance status (PS) 0 or 1

- ECOG PS 2 based on immobility from myeloma bone disease alone allowed at the
discretion of treating physician

- Creatinine ≤ 2.0 mg/dL

- ANC ≥ 1,000/mm³

- Platelet count ≥ 75,000/mm³

- Hemoglobin ≥ 8.0 g/dL

- Proteinuria ≤ 1 g/dL by 24-hour urine collection (excluding monoclonal protein)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 4 weeks after
completion of study treatment

- No bleeding diathesis

- No hypertension (defined as BP > 150/100 mm Hg)

- No active bleeding, healing or nonhealing wound, ulcer, or bone fracture (excluding
fractures secondary to myeloma)

- No active ulcerative disease including, but not limited to, any of the following:

- Peptic ulcer disease

- Ulcerative esophagitis

- Ulcerative colitis

- Crohn's disease

- LVEF ≥ 50% by 2-dimensional ECHO or MUGA scan

- No NYHA class III or IV heart disease

- No other active malignancy except for nonmelanoma skin cancer or in situ cervical or
breast cancer

- No active infection

- No other comorbidity that would interfere with study compliance

- No transient ischemic attack, cerebrovascular accident, or myocardial infarction
within the past year

- No abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within
the past 6 months

- No significant traumatic injury within the past 28 days

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No more than 2 prior antimyeloma treatment courses, except for bisphosphonates

- No standard or experimental drug therapy, other than ongoing bisphosphonate treatment
and/or epoetin alfa, within the past 28 days

- No experimental non-drug therapy within the past 28 days

- Palliative radiation therapy within the past 28 days allowed provided ≤ 3 sites of
bone disease was irradiated

- No prior bevacizumab or other experimental antiangiogenic agents other than
thalidomide or lenalidomide

- No minor surgical procedures, fine-needle aspiration, or core biopsies within the
past 7 days

- No major surgical procedure or open biopsy within the past 28 days

- No concurrent corticosteroids

- Chronic steroids ≤ 20 mg/day (prednisone equivalent) for disorders other than
myeloma (i.e., adrenal insufficiency, rheumatoid arthritis) allowed

- No other concurrent investigational therapy

- No other concurrent systemic antineoplastic therapy including, but not limited to,
the following:

- Cytotoxic chemotherapy

- Immunotherapy

- Hormonal therapy

- Monoclonal antibody therapy

- Concurrent bisphosphonates allowed